PTN - Palatin Technologies Inc Stock Price, Fair Value and News

$17.25-2.38 (-12.12%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PTN Price Action

Last 7 days

1.6%

Last 30 days

165.4%

Last 90 days

91.7%

Trailing 12 Months

-68.1%

PTN RSI Chart

PTN Valuation

Market Cap

29.4M

Price/Earnings (Trailing)

-6.11

Price/Sales (Trailing)

7.41

EV/EBITDA

-1.16

Price/Free Cashflow

-1.85

PTN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PTN Fundamentals

PTN Revenue

Revenue (TTM)

4.5M

Rev. Growth (Yr)

92.39%

Rev. Growth (Qtr)

92.39%

PTN Earnings

Earnings (TTM)

-4.8M

Earnings Growth (Yr)

159.79%

Earnings Growth (Qtr)

309.77%

PTN Profitability

Operating Margin

97.83%

EBT Margin

-616.33%

Return on Equity

-1.2K%

Return on Assets

-55.79%

Free Cashflow Yield

-54.17%

PTN Investor Care

Shares Dilution (1Y)

335.51%

Diluted EPS (TTM)

-22.6

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	5.9M	4.5M	0	0
2023	3.9M	4.9M	6.1M	7.1M
2022	1.2M	1.5M	2.2M	2.9M
2021	343.1K	568.1K	793.2K	1.0M
2020	15.2M	118.0K	0	0
2019	62.0M	60.3M	45.3M	30.2M
2018	67.1M	67.1M	65.4M	63.7M
2017	40.0M	67.1M	67.1M	67.1M
2015	10.8M	13.0M	0	0
2014	0	0	6.5M	8.6M
2013	2.2M	4.3M	0	0
2012	424.2K	73.7K	50.8K	45.4K
2011	0	1.5M	1.1M	774.6K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Palatin Technologies Inc

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

CEO	Dr. Carl Spana Ph.D.
WEBSITE	https://palatin.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	33

Palatin Technologies Inc Frequently Asked Questions

What is the ticker symbol for Palatin Technologies Inc? What does PTN stand for in stocks?

PTN is the stock ticker symbol of Palatin Technologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Palatin Technologies Inc (PTN)?

As of Wed Dec 03 2025, market cap of Palatin Technologies Inc is 29.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTN stock?

You can check PTN's fair value in chart for subscribers.

Is Palatin Technologies Inc a good stock to buy?

The fair value guage provides a quick view whether PTN is over valued or under valued. Whether Palatin Technologies Inc is cheap or expensive depends on the assumptions which impact Palatin Technologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTN.

What is Palatin Technologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, PTN's PE ratio (Price to Earnings) is -6.11 and Price to Sales (PS) ratio is 7.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Palatin Technologies Inc's stock?

In the past 10 years, Palatin Technologies Inc has provided -0.324 (multiply by 100 for percentage) rate of return.